Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Hera Biotech Closes Oversubscribed $1.9 Million Seed Raise For Novel Diagnostic Test for Endometriosis

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support the company’s commercialization strategy for its category-defining non-surgical diagnostic test for endometriosis, MetriDx™. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the US FDA.

Investors in this round include primarily female supporters from individual sources and investment firms Coyote Ventures, Stella Angels, Althea Group Ventures, and the Kendra Scott Women’s Entrepreneurial Leadership Institute. The company intends to kick off a Series A raise of $15 million in late 2022 to support commercial launch of its product in 2024.

“Our seed round was oversubscribed by nearly 100% from our original goal – which is an enthusiastic validation of our technology and the need for a solution for this pervasive and persistent, yet unsolved problem, in women’s health,” commented Founder and CEO Somer Baburek, MBA.

“The Kendra Scott Women’s Entrepreneurial Leadership Institute (KS WELI) at The University of Texas at Austin is thrilled to be part of Hera Biotech’s successful seed round through their wins at our Fall 2021 Female Founder Pitch Competition and Spring 2022 Dream to Venture events,” said Lesley Robinson, director of the KS WELI. “We are dedicated to supporting empowered women with the entrepreneurial spirit that can change the world, and Hera’s mission shines an important light on women’s health.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine